Biodesix, Inc.

Equities

BDSX

US09075X1081

Healthcare Facilities & Services

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
1.43 USD -0.69% Intraday chart for Biodesix, Inc. +5.93% -22.28%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Biodesix Strikes New Research Deal With Memorial Sloan Kettering Cancer Center MT
Biodesix Announces New Master Collaborative Research Agreement with Memorial Sloan Kettering Cancer Center CI
Transcript : Biodesix, Inc., Q4 2023 Earnings Call, Mar 01, 2024
Biodesix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Biodesix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Biodesix, Inc. Provides Revenue Guidance for the Year 2024 CI
Earnings Flash (BDSX) BIODESIX Posts Q4 Revenue $14.7M MT
Biodesix, Inc. Enhances Access to Nodify Lung Testing with Launch of New Blood Draw Method CI
Transcript : Biodesix, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Earnings Flash (BDSX) BIODESIX Reports Q3 Revenue $13.5M, vs. Street Est of $14.4M MT
Biodesix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Biodesix, Inc. Provides Revenue Guidance for the Year 2023 CI
Transcript : Biodesix, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 12:15 PM
Biodesix, Inc. Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer CI
Biodesix, Inc. Announces Presentation of New Nodify XL2(R) Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer CI
Transcript : Biodesix, Inc., Q2 2023 Earnings Call, Aug 07, 2023
Biodesix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Earnings Flash (BDSX) BIODESIX Reports Q2 Revenue $11.9M, vs. Street Est of $11.7M MT
Biodesix, Inc. Reaffirms Revenue Guidance for the Year 2023 CI
Biodesix Says Study Evaluating Nodify XL2 Test for Benign Lung Nodules Achieves Primary Endpoint; Shares Rise Pre-Bell MT
Biodesix, Inc. Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating That the Nodify XL2 Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules CI
Biodesix, Inc. Receives Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid Services CI
Biodesix Completes Enrollment of Study Assessing Clinical Utility of VeriStrat Test MT
Biodesix Completes Enrollment of Insight Study Assessing Clinical Utility of the Veristrat®? Blood-Based Host Immune Classifier CI
Biodesix, Inc. Announces Resignation of Ryan Siurek as Chief Accounting Officer, Effective July 3, 2023 CI
Chart Biodesix, Inc.
More charts
Biodesix, Inc. (Biodesix) is a data-driven diagnostic solutions company. Biodesix is focused on using technologies with its artificial intelligence platform to discover, develop, and commercialize solutions for clinical unmet needs in lung disease. Biodesix is providing diagnostic testing services associated with blood-based lung tests; coronavirus disease tests and providing biopharmaceutical companies with services that include diagnostic research, clinical research, development, and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. Its blood-based lung cancer tests include Nodify XL2 and Nodify CDT tests, and GeneStrat and VeriStrat tests. Biodesix also offers SARS-CoV-2 tests under the Biodesix WorkSafe testing program, such as Bio-Rad SARS-CoV-2 ddPCR test, Platelia SARS-CoV-2 Total Ab test and cPass SARS-CoV-2 Neutralizing Antibody testing.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.44 USD
Average target price
3.5 USD
Spread / Average Target
+143.06%
Consensus
  1. Stock
  2. Equities
  3. Stock Biodesix, Inc. - Nasdaq
  4. News Biodesix, Inc.
  5. Biodesix : Names Ryan Siurek as Chief Accounting Officer